Brief: Cosmo: successful outcome of phase III clinical trial for Rifamycin SV MMX
06/06/2016 06:01
June 6 (Reuters) - Cosmo Pharmaceuticals SA COPN.S :
* Cosmo announces successful outcome of phase III clinical trial for Rifamycin SV MMX
Source text for Eikon: ID:nTEN9s84ra
Further company coverage: COPN.S
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Cosmo Chemical
See all newsBrief: Cosmo Chemical Co Ltd Wins 15.5 Billion Won Order
US to award $3 billion to 25 projects for battery manufacturing sector
Brief: Cosmo Chemical Co Ltd Wins 799 Billion Won Order
Brief: Cosmo Chemical To Conduct Capital Increase Of 117.5 Billion Won
Brief: Cosmo Chemical To Invest 70 Billion Won In Facility Expansion